U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
48.65-0.24 (-0.50%)
At close: 4:00PM EDT

48.01 -0.64 (-1.31%)
After hours: 5:30PM EDT

People also watch
  • Doctor: Agree. P2 study problem is dosing issue. Not efficacy. Dosing needs tweaking. Nothing changed. Strong partnership (ABBV). Good balance sheet. Institutional support. Disruptive technology. Buy the dip. & Relax
  • Surely an over reaction?

    Even if Ingrezza is only ever approved for TD we should be pricing higher than this.
  • I read that article out today - found in the summary section - and learned something I didn't know. TD is currently controlled by benzodiazapines - xanax and the like - and ever-increasing doses have to be used.
    That is absolutely horrible. Benzos eventually turn into a total nightmare for many people using them long term - even under the strictest supervision. I've been through it and it's awful...they seem benign at first, but when you stop you can really be in trouble. It takes a long to get over them, and it's not pretty.
    This makes me feel even better about being invested in NBIX - Ingrezza is a major improvement for people already suffering.
    I started out in biotech by investing in Gilead, and pricing controversy aside, I was proud to be investing in a company eradicating a miserable disease. This is what makes biotech great.
  • When they released that PR saying that they were going to report data at the upcoming conference, I was sure this was in the bag - I even added a little at 52. Well...market is being fairly gentle about this after hours...that's encouraging. Also, I personally believe the explanation about dosing, and that this just needs a little tinkering to get right. I was really counting on this one, though. Biotech has been rough lately.
  • Buy on the dip. They just need a big sister to teach them PK.
  • May has been a bad week for biotech, today is particularly atrocious due to politics...and we're still flirting around our 52-week high. Tourette's data is positive. I have no doubt.
  • Perhaps a short-term pull back is more likely before the next rally on NBIX? google aw-esomeSTOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • How much will it pop if TS pediatric data is positive? Glta
  • What goes up must come down. I will buy at $25.
  • still short, still covering at $40. rinse and repeat. lot closer to $40 after today!
  • Wow, drop 8% after hour.
  • Politics effect, staying long, all the good news still ahead.
  • im Out
  • it's done below $25.00 sooon
  • H.C. Wainwright issues a 130 PT target for NBIX.
    These analyst PTs have to be taken with a grains of salt, but I'm feeling really good about NBIX right now...and about the Tourette's data coming soon.
  • Which date will they announce the pediatric results??
  • Tree shaking before earnings
  • still short, still covering at $40.
  • I've owned NBIX for years, a sizable position and looks like I'll finally be rewarded. However HC Wainwrights ridiculous PT of $100 then $130 is not to be taken seriously under any assumptions. Besides underwriting NBIX's latest convertible offering.. which certainly makes them less objective, look at their home page and then view their underwriting offerings. (Transactions) Majority of them are "whose who" of struggling to survive companies.. NWBO, AEZS, Celsion, CYtrx and others. Lots of sub $1 offerings.
    On a positive note many other analysts have had a strong buy recommendation with realistic PT of $65-$85 which still represent awesome potential. Other drug approvals in their pipeline along with takeover interest would be needed to see those levels though.
  • I'm counting on NBIX to redeem this totally #$%$ month. Release the data!!!!